A Phase 1b/2, Multicenter, Single Arm Study of RBN-2397 in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (SCCL)
Latest Information Update: 30 Nov 2023
At a glance
- Drugs Atamparib (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Ribon Therapeutics
- 30 Nov 2023 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
- 30 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 31 May 2023 Planned End Date changed from 24 Aug 2024 to 1 Dec 2023.